Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -4.9% | -8.5% |
ROCE | 46.5% |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 1.4 | 1.4 |
Pr/Book | 190.5 |
Latest | F'cast | |
---|---|---|
Revenue | 25.0% | 7.2% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-18 | 6.13 | (1.49) | (7.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-19 | 5.04 | (3.12) | (12.40)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-20 | 6.74 | (0.65) | (1.50)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 10.09 | 0.25 | 1.40p | 90.4 | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 12.61 | (0.62) | (1.30)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-23 | 13.52 | (1.15) | (3.05)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | 16.00 | 0.62 | 1.10p | 46.8 | n/a | n/a | n/a | 0.0% |
31-Dec-25 | 17.33 | 1.88 | 5.10p | 10.1 | 0.0 | +364% | 3.00p | 0.0% |
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
Notice of Results | 30-Apr-2024 | 07:00 | RNS |
COG spin-out Monument Therapeutics accesses ... | 23-Apr-2024 | 07:00 | RNS |
Total Voting Rights and Block Listing Return | 02-Apr-2024 | 16:20 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 51.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 104.00 |
52 Week Low | 48.80 |
Volume | 9,030 |
Shares Issued | 35.15m |
Market Cap | £18.10m |
RiskGrade | 282 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:10 | 2,000 @ 51.10p |
14:16 | 3,891 @ 51.40p |
13:25 | 116 @ 51.64p |
10:03 | 351 @ 51.00p |
08:13 | 2,500 @ 51.15p |
Chair | Steven John Powell |
CEO | Matthew Stork |
CFO | Stephen Symonds |
You are here: research